THX PHARMA SACA (ALTHX.PA) Stock Price & Overview
EPA:ALTHX • FR0013286259
Current stock price
The current stock price of ALTHX.PA is 3.28 EUR. Today ALTHX.PA is down by -1.35%. In the past month the price increased by 8.25%. In the past year, price increased by 741.03%.
ALTHX.PA Key Statistics
- Market Cap
- 47.462M
- P/E
- N/A
- Fwd P/E
- 31.84
- EPS (TTM)
- -0.36
- Dividend Yield
- N/A
ALTHX.PA Stock Performance
ALTHX.PA Stock Chart
ALTHX.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ALTHX.PA. When comparing the yearly performance of all stocks, ALTHX.PA is one of the better performing stocks in the market, outperforming 99.57% of all stocks.
ALTHX.PA Earnings
ALTHX.PA Forecast & Estimates
9 analysts have analysed ALTHX.PA and the average price target is 4.49 EUR. This implies a price increase of 36.83% is expected in the next year compared to the current price of 3.28.
ALTHX.PA Groups
Sector & Classification
ALTHX.PA Financial Highlights
Over the last trailing twelve months ALTHX.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 5.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.91% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALTHX.PA Ownership
ALTHX.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.57 | 99.338B | ||
| SNW | SANOFI | 9.47 | 98.344B | ||
| SAN | SANOFI | 9.43 | 98.211B | ||
| 1MRK | MERCK KGAA | 15 | 51.435B | ||
| MRK | MERCK KGAA | 14.66 | 51.087B | ||
| UNC | UCB SA | 24.1 | 49.503B | ||
| UCB | UCB SA | 23.02 | 48.063B | ||
| 1BAYN | BAYER AG-REG | 9.29 | 40.142B | ||
| BAYN | BAYER AG-REG | 9.15 | 39.267B | ||
| IPN | IPSEN | 12.65 | 13.359B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.8 | 10.335B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.561B | ||
| VIRP | VIRBAC SA | 17.76 | 3.222B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALTHX.PA
Company Profile
THX Pharma engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 10 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Company Info
IPO: 2017-10-30
THX PHARMA SACA
60, Avenue Rockefeller - Pepiniere Laennec
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 10
Phone: 33188897031
THX PHARMA SACA / ALTHX.PA FAQ
What does THX PHARMA SACA do?
THX Pharma engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 10 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
What is the stock price of THX PHARMA SACA today?
The current stock price of ALTHX.PA is 3.28 EUR. The price decreased by -1.35% in the last trading session.
What is the dividend status of THX PHARMA SACA?
ALTHX.PA does not pay a dividend.
How is the ChartMill rating for THX PHARMA SACA?
ALTHX.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is ALTHX.PA stock listed?
ALTHX.PA stock is listed on the Euronext Paris exchange.
Can you provide the market cap for THX PHARMA SACA?
THX PHARMA SACA (ALTHX.PA) has a market capitalization of 47.46M EUR. This makes ALTHX.PA a Nano Cap stock.
Who owns THX PHARMA SACA?
You can find the ownership structure of THX PHARMA SACA (ALTHX.PA) on the Ownership tab.